Annual report and Consolidated accounts 2025

The information was provided for publication on May 5, 2026

PROLIGHT
Diagnostics you can count on

TABLE OF CONTENTS

2025 in brief

FIRST QUARTER

- Positive patent decision for the core Psyros technology.
- Second positive patent decision for the Psyros technology.
- Positive preclinical data reported.

SECOND QUARTER

- Study demonstrating rapid integration of biomarkers onto the Psyros POC platform.
- First two European patents granted for the Psyros technology.
- MicroFlex patent approved in the United States.
- Resolution to carry out a rights issue.
- Fredrik Alpsten elected Chairman of the Board at the Annual General Meeting.
- Positive data reported from patient blood study at St Thomas' Hospital, London.

THIRD QUARTER

- Rights issue fully subscribed.
- Patent approval for Psyros technology in Japan.
- Psyros platform presented at ADLM 2025 in Chicago.
- Positive European patent decision for a third Psyros patent.

FOURTH QUARTER

- Assay design freeze achieved for the Psyros cartridge.
- Third Psyros-related patent granted by the European Patent Office (EPO).
- Preparations initiated for clinical performance study.
- Extraordinary General Meeting held on 19 November 2025.

SIGNIFICANT EVENTS AFTER YEAR-END

- Design freeze achieved for the Psyros instrument.
- Scale-up of cartridge manufacturing at FlexMedical Solutions.
- Strong interest in the Psyros POC system at the international WHX Labs congress.
- Positive results reported for traumatic brain injury (TBI) biomarkers in collaboration with BRAINBox Solutions, confirming broad platform potential.
- Selected as semi-finalist in the ADLM 2026 Disruptive Technology Award Competition.
- Prolight secures second patent in Japan for the Psyros technology.

Financial calendar

May 26, 2026
Interim Report Q1

May 26, 2026
Annual General Meeting

August 27, 2026
Interim Report Q2

November 26, 2026
Interim Report Q3

CEO statement

A Year of Focus and Clear Progress Towards Commercialisation.

2025 marked a pivotal year for Prolight. We took decisive and measurable steps in our transition from a research and development focused organisation to a company with a clear commercial trajectory. Following years of technology development, we reached several important milestones that reduced both technical and commercial risk and established a solid foundation for the final phase ahead of market introduction.

A key priority during the year was preparing the Psyros® platform for industrialisation. We achieved assay design freeze for the Psyros cartridge, confirming its final configuration and performance characteristics and effectively locking the assay chemistry. This milestone is essential for both the upcoming clinical performance study and future manufacturing. In parallel, together with our contract manufacturer FlexMedical Solutions, we advanced the scale-up of cost-efficient production of disposable cartridges to support initial launch volumes and enable future capacity expansion.

At the same time, we completed a fully functional commercial POC system, which was presented publicly for the first time to potential partners and end users. During the autumn, we conducted an extensive preclinical evaluation of approximately 30 instrument prototypes. The results confirmed the system's technical performance and provided valuable insights for a limited number of targeted improvements focused on long-term robustness and scalability. In April 2026, we formally achieved design freeze for the instrument, marking a large and decisive step towards scalable manufacturing and clinical use. The completed design enables pilot production of instruments to be used for verification, validation, followed by the regulatory clinical performance study.

We also reported positive whole blood data from cardiac patients at St Thomas' Hospital in London, which have played an important role in our ongoing discussions with potential industrial partners worldwide.

Our collaboration with the US-based BRAINBox Solutions, initiated at the ADLM congress, provides strong external validation of the Psyros platform's flexibility and breadth. Within this collaboration, we have successfully analysed biomarkers in traumatic brain injury (TBI), demonstrating both the platform's broad clinical applicability and its ability to be rapidly adapted to new indications. The project is fully funded by BRAINBox and has progressed into the next phase in 2026, involving the evaluation of 260 patient samples from an ongoing pivotal registration study in the United States.

This partnership further strengthens our position and highlights the attractiveness of Psyros to global diagnostics companies seeking scalable, cost-efficient POC solutions with rapid time to results and multiplexing capabilities.

Market interest in the Psyros platform was strong throughout 2025 and has continued into 2026. At major international congresses, including ADLM in the United States and WHX in Dubai, as well as in our ongoing partner dialogues, the platform generated significant interest. This has been driven by its unique combination of ultra-sensitive performance, rapid turnaround times and cost-efficient disposable cartridges. These interactions have provided valuable insights into market requirements, clinical applications and our competitive positioning. Most recently, further recognition of the platform's potential was demonstrated by Prolight being selected as a semi-finalist in the prestigious ADLM 2026 Disruptive Technology Award Competition.

From a financial perspective, we maintained strict cost discipline and clear prioritisation of resources. During the year, we successfully completed a fully subscribed rights issue without underwriters, strengthening our balance sheet and securing funding for key development activities. Our organisation has remained lean and focused, with a strong emphasis on initiatives that support long-term value creation.

We also continued to strengthen our intellectual property portfolio. During the year, several additional patents related to the Psyros technology were granted by both European and Japanese patent authorities. This combined patent protection further strengthens the protection of the platform's single-molecule counting technology and its long-term commercial value, as further demonstrated by securing a second patent for the Psyros technology in Japan in April 2026.

Market feedback, including interactions with healthcare end users, industry participants and key opinion leaders, has been valuable and has strengthened our conviction that the Psyros platform addresses real and pressing clinical needs.

I would like to extend my sincere thanks to our employees, partners and shareholders for your continued commitment and support. Through focused execution and disciplined progress, we have taken important steps towards realising the full potential of the Psyros platform. I look forward to updating you as we continue this journey.

Lund May 5 2026

Ulf Bladin
CEO Prolight Diagnostics (publ)

Safe point-of-care test enable faster diagnostics

Prolight Diagnostics has, over a long period, observed a sharply increasing demand in the market for user-friendly and near-patient analysis systems, so-called Point-of-Care ("POC") systems. A couple of examples are the mergers and acquisitions that have taken place. For example, Roche's acquisition of LumiraDx for 295 MUSD 2023 and bioMerieux's purchase of Spinchip in 2025 for 138 MEURO and the purchase of Specific Diagnostics for 417 MUSD in 2022. Additionally, Thermo Fisher Scientific's acquisition of Mesa BioTech in 2021 for USD 450 million and Abbott's acquisition of Alere for USD 5.8 billion already in 2016 show the greatly increased interest.

Primary and elderly care, emergency departments and ambulances demand fast, reliable blood test results when the patient is first examined instead of being forced to submit blood samples to hospital laboratories and wait hours or days for results, which is currently the case. Access to point-of-care analyses is especially important in acute conditions, such as for patients exhibiting acute chest pain and suspected myocardial infarction. In these situations, it is critical to make an early and correct diagnosis and initiate adequate treatment to save lives.

To meet this demand, Prolight is developing a new and flexible POC system, Psyros, which can perform In-Vitro Diagnostic (IVD) tests with the same sensitivity and precision as hospital laboratories but with the difference that test results can be given already within ten minutes or less. By obtaining these test results early in the patient care continuum, doctors and healthcare professionals can make the correct diagnosis and prioritise adequate resources for the right patient. As a result, substantial cost savings can also be realised in the heavily burdened healthcare system.

The new digital immunoassay technology was incorporated into Prolight in early 2022 through the acquisition of the British company Psyros Diagnostics Ltd, which has developed a new, cutting-edge POC technology for digital immunoassay. The wholly owned subsidiary Psyros Diagnostics currently has a highly competent team with long and broad experience in IVD development, especially in POC tests and POC systems. The team has unique competencies and experiences vital to the company's continued development.

Prolight's pioneering IP-protected POC technology counts individual molecules digitally from a drop of blood. This proprietary technology, which also has the possibility of multiplexing (testing several biomarkers at the same time), enables the measurement of biomarkers with extremely low detection levels (femtomolar 10-15) within approximately 10 minutes or less. To Prolight's knowledge, there is no other existing digital POC system deemed capable of performing these analyses at extremely low concentrations with such simplicity, precision, and low production costs. The system consists of an easy-to-use disposable cartridge and a portable analysis unit. Only a drop of blood is required to perform the test.

The cutting-edge technology will first be used to develop a diagnostic POC test that measures the protein troponin with high sensitivity and accuracy to aid in the rule-in and rule-out of myocardial infarction. By measuring the biomarker troponin, which is released from the heart into the bloodstream during the acute phase of myocardial infarction, the test helps to make a rapid diagnosis. Elevated levels of the protein troponin in the blood are a sign of damage in the heart muscle cells. The test places great demands on sensitivity and precision and has a substantial global sales potential.

The technology also opens up the possibilities of being able to develop and analyze new POC tests in a number of different clinical areas that were previously only possible to carry out in specialized laboratories. Prolight has been able to demonstrate that its digital ultra-sensitivity immunoassay can measure low levels of specific proteins down to single-digit nanograms per liter (ng/L) with laboratory-grade reproducibility. These concentrations are indicative of what is required to rule out myocardial infarction with high-sensitivity troponin assays[1].

Proof-of-performance results were obtained partly in November 2022 by measuring the levels of thyroid-stimulating hormone (TSH) in human plasma samples, partly in June 2023 by measuring high-sensitivity troponin in serum samples, and also

in November 2023 when the company was able to show that the system for detecting single molecules provides equivalent performance in whole blood compared to plasma, without the need to separate the cells from the sample. This reduces complexity and paves the way for an extremely competitive price level.

The final development work focuses on optimizing the IP-protected POC technology for digital immunoanalysis. An extensive preclinical evaluation of approximately 30 instrument prototypes confirmed the system's technical performance and provided a strong basis for implementing a limited number of targeted improvements focused on long-term robustness and scalability. In April 2026, the Company formally achieved design freeze for the instrument, marking a major and decisive step towards scalable manufacturing and clinical use. The completed design enables pilot production of instruments to be used for verification and validation, followed by the regulatory clinical performance study in Europe and the UK, and subsequently in the United States.

In March 2026, positive results were announced from a collaboration with BRAINBox Solutions, a leading developer of multimodal diagnostic and prognostic tests for traumatic brain injury (TBI).

The analytical evaluation demonstrated strong performance for a unique combination of three TBI biomarkers, highlighting how readily new markers can be transferred onto the Psyros platform, which is based on single-molecule counting. This further strengthens the platform's potential to improve patient care across a broad range of clinical applications.

The results are consistent with previously reported preclinical data demonstrating the ability of Psyros to deliver laboratory-quality results, detecting biomarkers at extremely low concentrations within minutes using only a small sample volume. The study was fully funded by BRAINBox, headquartered in Richmond, Virginia
.
Based on these results, Prolight and BRAINBox are now advancing to the next phase of the BRAINBox-funded programme, in which all three assays will be evaluated using a biobank comprising 260 patient samples.

These samples represent a subset of more than 2,000 samples available from BRAINBox's ongoing pivotal registration study, HeadSMART II, which is evaluating the company's diagnostic and prognostic test for mild traumatic brain injury, BRAINBox TBI, in preparation for regulatory submission to the U.S. Food and Drug Administration (FDA). The assay format utilises Psyros multiplex-capable test cartridges with dry reagents, enabling scalable and cost-efficient manufacturing—an important advantage in TBI and other conditions requiring high-precision measurement of multiple analytes.

Vision & Strategy

Vision

Prolight Diagnostics develops pioneering, innovative Point-Of-Care (POC) systems, for quick and reliable diagnosis of acute events, initially for myocardial infarction.

We offer our innovative POC systems to companies with global sales organisations in relevant POC segments.

Strategy

With Prolight's POC system, the ambition is to have test results available to doctors within ten minutes to allow rapid diagnosis and treatment when the patient is examined the first time, instead of spending critical time waiting for results from a hospital laboratory. This could be, for example, in an emergency department, a healthcare centre, an ambulance, or a care home.The ability to rule-in or rule-out myocardial infarction early in the care pathway will contribute to an efficient treatment for the right patients, allowing significant cost savings.

Initially, the focus will be on the measurement of the cardiac biomarker troponin, with high sensitivity and precision, which has a substantial global sales potential. The intention is also to include more biomarkers in many diverse clinical areas on the company's platform if they are deemed to be strategically and economically beneficial.

Point-of-Care

Point-of-Care – a rapidly growing global market

There is an acute awareness of the value of rapid, accurate, and efficient testing near the patient. The market demands that more tests are moved out from large hospital laboratories and closer to the patient and care giver. POC tests can also help reduce healthcare costs by giving faster results and more rapid treatment. Throughout the Covid pandemic, the use of POC testing increased substantially. This led to an acute awareness of the value of rapid, simple, and efficient testing and analysis near the patient. Most companies, healthcare providers, politicians and the general public realize the value of these tests, benefitting patients, clinicians, and healthcare in general. This interest has, in turn, created a need for new technologies that can meet the challenges of more demanding tests, whilst still being competitively priced.

According to Precedence research, the POC market is expected to grow from approximately USD 39.6 billion in 2024 to approximately USD 125.3 billion in 2034[2].

The global market for cardiac biomarkers
The global market for cardiac biomarkers was approximately USD 11.5 billion in 2024 and is expected to grow by approximately 7.2 percent per year until 2033[3].

Regarding POC tests for cardiac biomarkers, the market is driven by an increase in the number of people with heart disease and a growing awareness of the importance of early diagnosis to deliver timely and targeted care to the right patients.

The global market for troponin
The global market for troponin was approximately USD 1.6 billion in 2024 and is expected to grow by approximately 12.6 percent per year until 2033, reaching an estimated USD 4.2 billion by 2033[4].

Trends favoring the market development of POC tests
The main driving forces behind the general growth of POC tests are considered to be increased demand for central laboratory tests that are moved closer to the patient, e.g. to emergency departments, primary care, ambulances and nursing homes, rapid technical development, digitization within healthcare, increasing investments in research and development as well as an ageing population in the West.

[2] https://www.precedenceresearch.com/point-of-care-testing-market

[3] IMARC Group, IMARC group 2025: https://www.imarcgroup.com/cardiac-biomarkers-market

[4] https://www.custommarketinsights.com/press-releases/troponin-market-size/

Global market and Compound Annual Growth Rate (CAGR)



Groundbreaking ultra-sensitive POC technology

Prolight is poised to deliver the most innovative and best-in-class POC systems on the market

Prolight is well-positioned to deliver POC systems to satisfy several clinical unmet needs. These include high sensitive troponin, other biomarkers in many diverse clinical areas as well as assays currently not available at POC and multiplex assays for measuring several analytes simultaneously.

A new ground-breaking POC technology for digital immunoassay
Prolight has an entirely novel cutting-edge POC technology for digital immunoassay, which can count individual molecules from a single drop of blood. The unique IP-protected technology opens the possibility of developing several new POC tests and analysis in a wide range of clinical areas where many of them previously have only been possible to analyse in specialised laboratories. Further advantages of the digital immunoassay include its simplicity and low production costs.

Detection limit at the level of PCR tests, but with significantly faster response time
Today, PCR tests are recommended to confirm Covid, but the response time is lengthy, sometimes several hours to days, depending on the system. By using our digital assay technology, it is possible to count individual molecules at low levels, including viral particle proteins, such as coronavirus. As a result, sensitivity and accuracy can be as good or better than PCR tests currently offered on large central laboratory instruments. The large and highly significant difference between today's PCR tests and Prolight's innovative digital POC platform is that the response time can be reduced to just ten minutes or less.

May be the start of a paradigm shift in POC testing
This novel technology could mark the beginning of a paradigm shift in POC testing for clinical diagnostics. Some examples of possible future clinical areas are: Neuropathology (dementia, traumatic brain injuries), Immune system dysfunction (sepsis, autoimmune diseases), Sexually Transmitted Infections, Rapid virus detection such as Covid. The unique and IP-proteced technology behind the digital immunoassay will make it possible to test a range of biomarkers with high sensitivity and accuracy on a single POC instrument. Prolight believes that this technology could be a paradigm shift in POC testing for clinical diagnostics.

Next generation point of care platform
Future applications across many diverse clinical areas

Prolight has a strong patent portfolio

The patent portfolio for the Psyros single molecule counting technology
Prolight have six families of patent applications relating to the Psyros single-molecule-counting technology. The first five families are currently in the national / regional phases in a range of territories worldwide. The sixth patent application entered the PCT (patent cooperation treaty) international phase in November 2025.

The first 2 patents were granted in Europe in Q2 2025 by the European Patent Office (EPO) and have now been validated in the following 17 European jurisdictions: France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Belgium, Ireland, the Netherlands, Portugal, Sweden, Switzerland, Turkey, Denmark, Finland and Norway. This covers a population base of 540 million people. A third patent was granted in Europe in December 2025 and is currently going through the validation process.

The core patent for Psyros was granted by the Japan Patent Office (JPO) in July 2025 and in April 2026, a notice of allowance was received for the second patent for the Psyros technology in Japan.

Family 1 patents EP3987287 and JP7700055 protect the core technology and will remain in force until 2040.

Family 2 patent EP4264266 is an enhancement to the core technology and will remain in force until 2041.

Family 3 patent EP4496995 uses 2 wavelengths to enhance signal generation and will remain in force until 2042.

A divisional application of family 1 patent EP3987287 has also been filed (published as EP4549943) to seek greater scope for the core technology.

The patent situation for MicroFlex
For MicroFlex, the patent portfolio consists of six registered patents (three in the US, two in the EU, and one in Sweden) and three patent applications that have advanced to the national phase and are now being pursued in various territories.

One of the patent applications pertains to how the sampling tube can be directly integrated into the cartridge. This enables a very simple workflow for all types of clinical environments. No specially trained personnel are needed to pipette and centrifuge the blood sample. MicroFlex thus creates the conditions to offer a fully automated platform for immunodiagnostics.

The most recently approved patent in the United States in May 2025 provides protection for the unique technical composition of the MicroFlex analytical device and reaction chamber. The patent is a testament to the technological height of MicroFlex.

The approved patent from October 2024 concerns a European patent based on a groundbreaking solution for separating plasma from whole blood in a liquid-based consumable. The separation produces high-quality plasma, requires minimal physical space, and is performed in a short amount of time, unlocking new potential business opportunities by integrating the technology into other liquid-based disposable systems

About PCT and patent application process
Patent Cooperation Treaty (PCT) is an international agreement that allows you to obtain, with a single application, in one language, a novelty search and preliminary patentability assessment conducted by one authority for approximately 150 countries. For a PCT application to lead to a patent in a particular country (or territory, such as the EU), the application must be prosecuted at the respective patent office.

During the patent application process, it is normal for the reviewing authority to ask several questions, which Prolight and the company's legal representatives spend much time answering to achieve the strongest possible patent protection. This correspondence takes different amounts of time depending on each authority's questions. It is, therefore, challenging to give an exact date for when an individual patent application can be expected to be approved.

Owners

Owners list as of 2025-12-30

	Holdings 2025-12-31	Votes in %
FÖRSÄKRINGSAKTIEBOLAGET AVANZA PENSION	687,375	5.71
NORDNET PENSIONSFÖRSÄKRING AB	526,191	4.37
INTEGRATED TECHNOLOGIES LTD	493,720	4.10
STEVEN ANDREW ROSS	324,782	2.70
AILEEN JANE MCGETTRICK	318,295	2.64
PAUL BRENDAN MONAGHAN	318,295	2.64
JULIE RICHARDS	318,295	2.64
SWEDBANK FÖRSÄKRING AB	226,178	1.88
SEB LIFE INTERNATIONAL ASSURANCE	225,380	1.87
FREDRIK ALPSTEN	205,766	1.71
Total, 10 largest owners	**3,644,277**	**30.26**
Other	8,400,505	69.74
Total	**12,044,782**	**100.0**

Source: Euroclear

The company has outstanding warrants to employees of Psyros Diagnostics Ltd. of 8,304,510 (corresponding to 83 045 shares) and 80,703 (corresponding to 80,703 shares) and can thus cause dilution.

Prolight Diagnostics' share is traded on the NGM Growth Market, under the name PRLD.

Board of Directors

FREDRIK ALPSTEN
CHAIRMAN OF THE BOARD

Education and background: Fredrik Alpsten has a Bachelor of Science from the Stockholm School of Economics. Fredrik has earlier, among others, been CEO of Devyser Diagnostics AB, CEO of US-based Clinical Diagnostic Solutions Inc, CFO at Boule Diagnostics AB, CFO at IRRAS AB, CFO at Algipharma AB and CEO and CFO at Doxa AB. Previously, he was chairman at Personlig Almanacka Nordic AB, a board member at Binero Group AB, and at Pharmetheus AB. He is also currently the chairman of Biovica International AB, a chairman of Njuice AB, chariman of Winsty AB and an alternate board member of Fredrik Alpsten Consulting AB.

Shareholding as of 30/12/2025: 205,766 shares.

ULF BLADIN
BOARD MEMBER & CEO

Education and background: Ulf Bladin is a Bachelor of Medicine from Karolinska Institutet, holds a Master of Business Administration and an MSc from the Stockholm School of Economics. Ulf has previously been General Manager, Vice President of the EMEA region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, and Vice President with Global Responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia. He has also held leading commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dohme.

Shareholding private and via company as of 31/12/2025: 191,428 shares.

STEVE ROSS
BOARD MEMBER

Education and background: Steve Ross has two undergraduate degrees, one in chemistry, the other in mathematics with statistics, and he received his PhD from Edinburgh University in synthetic chemistry. He subsequently carried out postdoctoral research at The University of Utah (Royal Society Fellowship), the CNRS in Toulouse, France (Marie Curie Fellowship) and The University of Oxford. Steve Ross is a co-founder of Psyros and has worked in in-vitro diagnostics for over 15 years. His industrial career started in 2001 with PiezOptic, developing pyroelectric sensors for monitoring exposure to toxic gases. In 2006 he co-founded Vivacta, a start-up company using the same pyroelectric technology, this time for point-of-care clinical diagnostics.

Shareholding as of 30/12/2025: 324,782 shares.

AILEEN MCGETTRICK
BOARD MEMBER

Education and background: PhD in biochemistry and genetics at Oxford University followed by Postdoctoral Research Fellowships at Oxford and the Joslin Diabetes Center, Boston USA (affiliated to Harvard Medical School) researching the genetics of Type 2 diabetes. Aileen is co-founder of Psyros and has 15 years of experience in assay development for medical devices. From 2008 to 2018 in her role as Group Head of Assay Development she led multi-disciplinary teams for VC backed start-up Vivacta Ltd and subsequently the Novartis Near Patient Testing Unit (after acquisition of Vivacta by Novartis in 2012), specializing in detection of target analytes in whole blood for point of care diagnostics.

Shareholding as of 30/12/2025: 318,295 shares.

TOBIAS VOLKER
BOARD MEMBER

Education and background: PhD in Biochemistry and an MBA from INSEAD. Over the last decades, Tobias has strongly contributed to the development of point-of-care for heart disease but also in other disease areas. At Biosite, he led the international development of the Triage platform and launched the cardiac panel and the very first reimbursable BNP assay in Europe. Responsible for the launch of Quo-Test HbA1c at Quotient Diagnostics and participated in the reverse acquisition that later became EKF Diagnostics. Tobias gained further insight into the POC business while working at Cholestech, Alere and more recently at Expand Healthcare Consulting GmbH, where he was a high-level advisor to private companies and non-profit organizations. He has also been the responsible manager of the healthcare R&D group at SK Telecom. Board member of Ominilabs.

Shareholding as of 30/12/2025: 61,114 shares.

KIARASH FARR
BOARD MEMBER

Education and background: Kiarash Farr is a Master of Science in Engineering Physics from Royal Institute of Technology (KTH) Stockholm and Management Acceleration Program from (MAP) INSEAD. Kiarash has previously been Senior Vice President of Commercial Operations at Boule Diagnostics, Senior Director, Commercial Operations of the EMEA region at Hycor Biomedical, Sales Director Key account management at Thermo Fisher Scientific Immuno Diagnostics Division, and Business Director Asia at IBA with various leadership positions in Germany, China and India. He is currently board member of Perpetua Medical and CEO and founder of SiMind AB.

Shareholding as of 30/12/2025: 126,667 shares.

MARIA HOLMLUND
BOARD MEMBER

Education and background: Bachelor's Degree in Chemistry and Biology from Uppsala University and a Master of Science from the University of North Carolina. 30 years of experience in the life science and diagnostics field. Worked in senior positions with a focus on marketing in international diagnostics companies such as Pharmacia Diagnostics, Boehringer Mannheim, Roche Scandinavia, Phadia and Thermo Fisher Scientific. Board member of Biovica AB. CEO of Prolight Diagnostics AB between 2016-2020.

Shareholding as of 30/12/2025: 21,685 shares.

Prolight Group Management

ULF BLADIN
CEO

Education and background: Ulf Bladin is a Bachelor of Medicine from Karolinska Institutet, holds a Master of Business Administration and an MSc from the Stockholm School of Economics. Ulf has previously been General Manager, Vice President of the EMEA region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, and Vice President with Global Responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia. He has also held leading commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dohme.

Shareholding private and via company as of 31/12/2025: 191,428 shares.

HENRIK LJUNG
CFO

Education and background: Henrik Ljung has a Bachelor's degree in economics from Lund University. He has a solid background as a chartered accountant and many years of experience as a CFO in listed companies, such as Acconeer AB, Carbiotix AB and Qlife Holding AB, and AB Sardus. Henrik has extensive experience of companies in an early stage of development, as well as company acquisitions.

Shareholding as of 30/12/2025: 10,211 shares.

KARL BULLEN
COO

Education and Background: Karl holds a Bachelor of Engineering from the University of Greenwich. Karl has a proven track record within operational leadership roles having a wide range of experience in regulated manufacturing encompassing aerospace, medical devices and pharmaceuticals. Karl previously held the position of Head of Operations for Swedish contract pharmaceutical manufacturer Recipharm and has also held manufacturing leadership roles at defence giant BAE Systems and medical science company Olympus. Karl has a strong knowledge of lean principles and operational excellence that has been used to develop high performing teams and effective processes that deliver results.

Shareholding as of 30/12/2025: 50,231 shares, 2,500,127 options (corresponding to 25,001 shares) and 32,503 options (corresponding to 32,503 shares) through incentive programs.

Management Report

ACTIVITIES

Prolight Diagnostics AB, org no. 556570-9499, develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction. With Prolight's POC system, the ambition is to have test results available to doctors within ten minutes to allow rapid diagnosis and treatment when the patient is examined the first time, instead of spending critical time waiting for results from a hospital laboratory. This could be, for example, in an emergency department, a healthcare centre, an ambulance, or a care home.

A group was formed on March 1, 2022 when Prolight Diagnostics AB completed the acquisition of the English subsidiary Psyros Diagnostics Ltd.

The company's share is traded under the code name PRLD on the NGM Growth Market marketplace. The parent company is headquartered in Lund.

The Group's development during the period, 1 January to 31 December 2025

(figures in brackets refer to the corresponding period in the previous year)

REVENUE

During the product development year, the Group has no sales and net turnover.

Other income for the period amounted to 26,854 (19,133) thousand SEK, consisting mainly of government grants and tax-related grants received in the English subsidiary Psyros.

COSTS AND RESULTS

The Group's total operating expenses during the year amounted to 95,452 (63,636) thousand SEK.

Capitalized work for own account amounted to 15,349 (17,233) thousand SEK and refers to costs for the Group's product development.

FINANCING AND CASH FLOW

Cash flow from operating activities amounted to -37,005 (-27,946) thousand SEK.

The Group's cash flow from investing activities amounted to -19,729 (-22,133) thousand SEK and consists mainly of capitalized development costs of -15,349 (-17,232) thousand SEK during the period related to the Group's product development.

The total cash flow for the year was 24,702 (2,250) thousand SEK. The cash flow for the year includes a new share issue net of issue costs and set-offs of 81,437 thousand SEK. In the previous period's figures, a new share issue after issue costs of 52,329 thousand SEK was carried out.

Cash and cash equivalents amounted at the year end to 40,606 (15,734) thousand SEK.

EQUITY, RECEIVABLES AND LIABILITIES
(FIGURES IN BRACKETS REFER TO 2024-12-31)

Equity in the Group amounted to 169,347 (128,285) thousand SEK as of 31 December 2025. Provisions amounted to 14,419 (17,791) thousand SEK and consist of a deferred tax liability relating to the acquired technology platform in the English subsidiary Psyros. Current receivables amounted to 17,201 (14,385) TSEK. Current liabilities amounted to 9,664 (20,255) TSEK. The previous year's figures included 13,000 TSEK,which consisted of a liability to the former owners of Psyros Diagnostics Ltd for an estimated additional purchase price. Prolight and the former owners of the acquired Psyros Diagnostics Ltd have, inlight of the fact that certain development work has not been carried out in accordance with the timetable agreed by the parties in connection with the acquisition in 2022, agreed that the remaining additional purchase price of 13,000 TSEK will not be paid. It is noted for the sake of order that this agreement is only attributable to the parties' original agreement from January 2022 and that there has been no change in the Company's (previous) communication regarding the development work.

Total assets as of December 31, 2025 amounted to 193,431 (166,331) TSEK and consist mainly of acquired intangible assets of 69,994 (85,922) TSEK relating to the technology platform in Psyros Diagnostics Ltd. and intangible assets of 57,297 (43,793) TSEK relating to capitalized work for own account.

The equity ratio was 88 percent (77).

Parent company development during the period January 1 to December 31, 2025

REVENUE

Other income during the year amounted to 3,283 (3,211) TSEK. The income consisted mainly of invoiced costs to Psyros for management services, exchange rate gains and distribution income from NGM.

COSTS AND RESULTS

The company's total operating expenses during the year amounted to 11,063 (9,388) thousand SEK. The costs consisted mainly of external costs relating to consulting costs for management services and an impairment of patent costs for MicroFlex of 1,836 thousand SEK. Net financial items were for the period -61,216 (-41,397) thousand SEK. The financial items include an impairment of investment in subsidiaries relating to the internal receivable from Psyros Diagnostics Ltd which has been converted into a shareholder contribution and amounts to 61,385 (41,986) thousand SEK. The result for the period amounted to -68,996 (-47,575) TSEK.

FINANCING AND CASH FLOW

Cash flow from operating activities amounted to -8,366 (-7,841) TSEK during the year.

Total cash flow for the year amounted to 24,620 (5,562) TSEK. The cash flow for the year includes a new share issue net of issue costs and set-offs of 81,437 TSEK.

Cash and cash equivalents at the end of the year amounted to 39,450 (14,830) TSEK.

EQUITY, RECEIVABLES AND LIABILITIES
(FIGURES IN BRACKETS REFER TO 2024-12-31)

Equity as of 31 December 2025 amounted to 93,055 (69,801) TSEK. Total assets as of December 31, 2025 amounted to 95,736 (85,792) thousand SEK and consist mainly of shares in Psyros Diagnostics Ltd of 55,768 (68,768) thousand SEK.

The equity ratio was 97 percent (81).

Significant events during the financial year

FIRST QUARTER

- Positive patent decision for the core Psyros technology.
- Second positive patent decision for the Psyros technology.
- Positive preclinical data reported.

SECOND QUARTER

- Study demonstrating rapid integration of biomarkers onto the Psyros POC platform.
- First two European patents granted for the Psyros technology.
- MicroFlex patent approved in the United States.
- Resolution to carry out a rights issue.
- Fredrik Alpsten elected Chairman of the Board at the Annual General Meeting.
- Positive data reported from patient blood study at St Thomas' Hospital, London.

THIRD QUARTER

- Rights issue fully subscribed.
- Patent approval for Psyros technology in Japan.
- Psyros platform presented at ADLM 2025 in Chicago.
- Positive European patent decision for a third Psyros patent.

FOURTH QUARTER

- Assay design freeze achieved for the Psyros cartridge.
- Third Psyros-related patent granted by the European Patent Office (EPO).
- Preparations initiated for clinical performance study.
- Extraordinary General Meeting held on 19 November 2025.

Significant events after the end of the financial year

- Design freeze achieved for the Psyros instrument.
- Scale-up of cartridge manufacturing at FlexMedical Solutions.
- Strong interest in the Psyros POC system at the international WHX Labs congress.
- Positive results reported for traumatic brain injury (TBI) biomarkers in collaboration with BRAINBox Solutions, confirming broad platform potential.
- Selected as semi-finalist in the ADLM 2026 Disruptive Technology Award Competition.
- Prolight secures second patent in Japan for the Psyros technology.

Risks and uncertainties

All business activity involves a degree of risk and an assessment of the future development and profitability of the business should be seen in this perspective. Prolight Diagnostics are exposed to a number of risks and uncertainties, which may have a negative impact on continued operations. Below is a selection of some of the risk factors and important conditions that are deemed to be relevant to the future development of the business. The risks described below are not the only risks faced by the Company. An overall evaluation must also include other sources of public information and a general assessment of the environment.

Risks associated with the business

COMPETITION AND ALTERNATIVE TECHNOLOGIES

The Company may be exposed to competition from several other companies with investments incorresponding segments. Several of these companies may have greater financial resources than Prolight Diagnostics. The general research and development in the areas in which the Company intends to be active may also negatively affect the ability to sell the products, as other methods or technologies may prove to be more advantageous to potential customers.

RISKS IN THE ORGANIZATION

The Company's business is dependent on the ability to recruit, develop and retain qualified employees. This risk factor may also include the dependence on key individuals that applies to the Company's subcontractors. Although management believes that the Company will be able to both attract and retain qualified key individuals, it cannot be guaranteed that this can be done on satisfactory terms against the competition from other companies in the industry or related industries. Losses of key personnel, as well as future failures to recruit people with the necessary skills, could have a negative impact on the company's sales, earnings capacity and results.

PRODUCT DEVELOPMENT/COMPONENT SHORTAGE

Prolight Diagnostics AB develops products with its own resources and has collaborations regarding product development with other companies. The main focus is currently on developing diagnostic systems according to the parent company and subsidiary's patented technology. If the Group's development activities do not achieve acceptable results, for example with regard to achieved results or later failure to implement intended collaborations with larger medtech companies, this could have a significant negative impact on operations. In this case, opportunities may be lacking to successfully develop or commercialize the products. It cannot be excluded that there is a risk that the Group's partners cannot deliver necessary components to the company, which could mean that products cannot be delivered according to order, which could significantly affect operations negatively.

EARNING CAPACITY AND CAPITAL NEEDS

The Company has historically operated at significant losses and still lacks cost-covering revenues. It is not certain that the Company will succeed in generating substantial and recurring revenues, and therefore it is not certain that positive results will be achieved in the future. It cannot be guaranteed that the Company will generate sufficient funds to finance the continued operations of the parent and subsidiary companies, nor can it be guaranteed that the necessary financing can be obtained on advantageous terms. Failure to obtain additional financing at the right time may result in the Company having to postpone, reduce, or terminate its operations.

RISKS IN SALES

Future earnings depend on the Company's success in entering into agreements for the sale or licensing of the Company's products and technology to create an installed base that could generate additional sales in the form of recurring diagnostic kits. There is a risk that Prolight Diagnostics will fail to enter into such agreements or that such agreements cannot be reached on terms as favorable as the Company desires. In addition, the Company's ability to sign successful agreements with partners depends, among other things, on the Company's reputation, financial strength, successful development work and the quality of the products.

AUTHORITY DECISIONS

In order to market products based on the Company's technology, Prolight Diagnostics, its partners and subcontractors may be required to obtain relevant permits from authorities. There is no guarantee that such permits will be obtained, or that the permits will be of the required scope. The licensing process may also be time- and capital-intensive, which may delay the launch of products on the market, negatively impacting the Company's results, financial position and cash flow.

INTELLECTUAL PROPERTY RIGHTS

The Company's competitiveness depends, among other things, on the ability to obtain, maintain and defend patents to protect its products. There is no guarantee that patent applications will result in approved patents, that approved patents can be maintained or that the patents provide sufficient protection to have commercial significance. Even if satisfactory patent protection is obtained, the costs of maintaining this protection can be significant, as can the costs of defending the patents in the event of possible infringement by third parties. Prolight Diagnostics has six approved patents for the Microflex technology and five for the Psyros technology relating to the markets in Sweden, the EU, Japan and the USA, which are priority markets. Other companies in the sector may also have intellectual property rights that could theoretically be claimed to infringe on Prolight Diagnostics' intellectual property rights. This could in such a case mean reduced revenues and increased costs for obtaining permission to exploit another company's intellectual property rights.

CUSTOMER FINANCING RISKS

After receiving an order, there may be risks that financing is not available for these products that are to be procured and are financed via public funds, insurance companies and partly private funds. Furthermore, the Company's goal is to enter into financing agreements with potential major partners, and there is no guarantee that these agreements will be completed as agreed.

COLLABORATORY AGREEMENTS

Prolight Diagnostics AB currently has certain agreements and may sign additional agreements for collaborations and distribution. Within all collaborations, there is a risk that one party will not fulfill its commitment. For example, a counterparty may end up in financial difficulties that make it impossible for this party to continue its commitment and also completely different circumstances may affect the conditions for continued collaboration. Future any agreements on market rights, etc. may develop in a worse way than anticipated and agreements within manufacturing and delivery agreements for goods may function unsatisfactory.

PRODUCT LIABILITY

Sales of products are always associated with risks that the product does not meet the requirements or that customers in other ways become dissatisfied with the results after using the product. It cannot be ruled out that customers will become dissatisfied with the results after using the product. It cannot be ruled out that customers will claim compensation based on product warranties to a greater extent than is included in the calculations made. It cannot be guaranteed that Prolight Diagnostics' insurance coverage against such compensation claims is sufficient to compensate for financial damage that may be incurred in connection with any future claims against the company.

POLITICAL RISKS

General funds may be a source of financing for future sales. Such funds are dependent on political positions and decisions. Prolight Diagnostics cannot predict in which markets such funds will be made available to the desired extent and thus constitutes a risk in the markets where sales efforts are being prepared.

FINANCING NEEDS AND CONDITIONS FOR CONTINUING OPERATIONS

Prolight will continue to further develop its products, which will entail additional costs. Both the size and timing of any capital needs depend on a number of factors, including success with product development, generated revenues and cooperation agreements. However, there is a risk that the Company may need additional capital in the future to be able to continue to operate and develop its operations at the pace and extent planned. There is a risk that the Company will then not be able to obtain the necessary capital on favorable terms. Future capital raising measures may result in dilution of the ownership in the Company for shareholders who choose not to participate in any upcoming new issues. There is a risk that the Company will then not be able to obtain the necessary financing or that such financing can be obtained on favorable terms for existing shareholders. A failure to obtain additional financing at the right time may mean that the Company must postpone, reduce, or terminate operations. At such a stage, it cannot be ruled out that this could lead to a situation where a material uncertainty could arise, which could thereby lead to significant doubts about the Company's ability to continue its operations in its current form.

Without additional capital, the Company is expected to be able to fund its ongoing operations with existing cash resources until the end of the third quarter of 2026. The Board of Directors is continuously evaluating various financing alternatives. The Board considers it likely that new financing will be secured during the summer, which is expected to cover the Company's liquidity needs.

Multi-year overview

Group

Multi year overview (amount in kSEK)	2025	2024	2023	2022 (10 months)
Net sales	0	0	0	0
Loss after financial items	-53,080	-26,937	-135,461	-10,230
Balance sheet total	193,431	166,331	169,233	207,913
Equity ratio (%)	88	77	79	99

Multi-year overview

Parent company

Multi year overview (amount in kSEK)	2025	2024	2023	2022	2021
Net sales	0	0	0	0	0
Loss after financial items	-68,996	-47,575	-153,129	-30,443	-6,855
Balance sheet total	95,736	85,792	111,570	187,729	149,133
Equity ratio (%)	97	81	86	99	98

Ownership structure

As of December 31, 2025, the largest shareholders was Avanza Pension 5,71%, Nordnet Pension 4,37%, Integrated Technologies Ltd 4,10%, Steven Ross 2,70%, Aileen Mc Gettrick 2,64%, Paul Monaghan 2,64%, Julie Richards 2,64%, Swedbank Försäkring AB 1,88%, SEB Life International Assurance 1,87%, Fredrik Alpsten 1,71%.

Allocation of accumulated deficit

The proposed appropriation of the Company's profit. (Amount in kSEK).

At the disposal of the Annual General Meeting is:	
Accumulated loss	-238,278
Premium fund	266,834
Loss of the year	-68,996
	-40,440
The Board proposes:	
Dividends to shareholders	0
To be carried forward	-40,440
	-40,440

Income statement
Group

Amount in kSEK	Note	2025-01-01 2025-12-31	2024-01-01 2024-12-31
Operating income etc			
Net sales		0	0
Activated work for own account		15,349	17,233
Other income	2	26,854	19,133
Total operating income		42,203	36,366
Operating expense			
Other external costs		-53,296	-41,483
Personnel costs	3	-22,503	-20,632
Depreciations and write down material and immaterial assets	4,5	- 19,635	-1,505
Other operating expenses		-18	-15
Total expenses		- 95,452	-63,636
Operating loss		**-53,249**	**-27,270**
Result from financial investments			
Other interest income and similar items		492	588
Other interests expenses and similar items		-323	-255
Total financial items		169	333
Loss after financial items		**-53,080**	**-26,937**
Taxes		3,372	0
Loss for the year		**-49,708**	**-26,937**
Attributable to			
Parent comany's shareholders		-49,708	-26,937
		-49,708	-26,937

Balance sheet
Group

Amount in kSEK	Note	2025-12-31	2024-12-31
ASSETS			
Subscribed capital unpaid		**90**	**0**
Fixed assets			
Itangible assets			
Capitalized expenditure on development work and similar work	4	127,276	127,855
Patent	5	15	1,860
		127,291	**129,715**
Tangible assets			
Equipment, tools, fixtures and fittings	6	8,243	6,497
		8,243	**6,497**
Total fixed assets		**135,534**	**136,212**
Current assets			
Current receivables			
Other receivables		14,409	14,283
Prepaid expenses and accrued income		2,792	102
		17,201	**14,385**
Cash and cash equivalents	9	40,606	15,734
Total current assets		**57,807**	**30,119**
TOTAL ASSETS		**193,431**	**166,331**

Balance Sheet
Group

Amount in kSEK	Note	2025-12-31	2024-12-31
EQUITY AND LIABILITIES			
Equity			
Share capital		120,448	70,209
Other paid in capital		279,881	237,870
Other equity		-181,274	-152,857
Loss for the year		-49,708	-26,937
Total equity		**169,347**	**12, 285**
Provisions			
Accrued tax liabilities		14,419	17,791
Total provisions		**14,419**	**17,791**
Current liabilities			
Accounts payables		6,351	3,785
Other liabilities		849	13,786
Accrued expenses and deferred income		2,464	2,684
Total current liabilities		**9,664**	**20,255**
TOTAL CURRENT LIABILITIES		**193,431**	**166,331**

Report over changes in shareholders equity, Group

Amount in kSEK	Share capital	Other Paid in capital	Other capital incl result for the period	Total share-holders equity
Opening balance 2025-01-01	**70,209**	**237,870**	**-179,794**	**128,285**
Profit for the year			-49,708	-49,708
Translation difference for the year			-1,479	-1,479
New share issue	50,239	50,149		100,388
Issuance costs		-8,139		-8,139
Closing balance 2025-12-31	**120,448**	**279,880**	**-230,981**	**169,347**

Amount in kSEK	Share capital	Non register sharecapital	Other Paid in capital	Other capital incl result for the period	Total share-holders equity
Opening balance 2024-01-01	**34,682**	**15,039**	**237,226**	**-153,955**	**132,992**
Profit for the year				-26,937	-26,937
Translation difference for the year				1,098	1,098
New share issue	35,527		2,739		38,266
New share issue in progress		-15,039	0		-15,039
Issuance costs			-2,095		-2,095
Closing balance 2024-12-31	**70,209**	**0**	**237,870**	**-179,794**	**128,285**

Cash flow statement
Group

Amount in kSEK	Note	2025-01-01 2025-12-31	2024-01-01 2024-12-31
Operating activities			
Operating loss		-53,249	-27,270
Adjustments for non-cash items	10	7,079	1,505
Interests received		492	588
Cash flow from operating activities before changes in working capital		**-45,678**	**-25,176**
Cash flow from changes in working capital			
Decrease(+)/increase(-) in operating receivables		-4,261	-4,017
Decrease(-)/increase(+) in operating liabilities		12,934	1,247
Cash flow from operating activities		**-37,005**	**-27,946**
Investment activities			
Investment in development		-15,349	-17,232
Investment in tangible assets		-4,381	-4,901
Cash flow from investment activities		**-19,730**	**-22,133**
Financing activities			
Share issue		81,437	52,329
Cash flow from financing activities		**81,437**	**52,329**
Cash flow for the period		**24,702**	**2,250**
Cash and equivalents at the beginnging of period		15,734	13,274
Exchange rate differences in cash		170	210
Cash and equivalents at the end of period	8	**40,606**	**15,734**

Income statement
Parent company

Amount in kSEK	Note	2025-01-01 2025-12-31	2024-01-01 2024-12-31
Operating income etc			
Net sales		0	0
Other income	2	3,283	3,211
Total other income		**3,283**	**3,211**
Operating expense			
Other external costs		-7,785	-7,848
Personnel costs	3	-1,423	-1,525
Depreciation and Write down material and intagible assets	5	-1,836	0
Other operating expenses		-18	-15
Total operating expenses		-11,063	-9,388
Operating loss		**-7,780**	**-6,177**
Result from financial investments			
Write-down of investment in subsidiary	7	-61,385	-41,986
Other interest income and similar items		492	588
Other interests expenses and similar items		-323	0
Total result from financial investments		-61,216	-41,398
Loss after financial items		**-68,996**	**-47,575**
Loss before taxes		**-68,996**	**-47,575**
Taxes		0	0
Loss for the year		**-68,996**	**-47,575**

Balance sheet
Parent company

Amount in kSEK	Note	2025-12-31	2024-12-31
ASSETS			
Subscribed capital unpaid		**90**	**0**
Fixed assets			
Intagible assets			
Patent	5	0	1,836
		0	**1,836**
Financial assets			
Participation in group companies	7,12	55,768	68,768
		55,768	**68,768**
Total fixed assets		**55,768**	**70,604**
Current assets			
Short term receivables			
Other receivables		300	255
Prepaid expenses an accrued income		128	103
		428	**358**
Cash and cash equivalentes	8	39,450	14,830
Total current assets		**39,878**	**15,188**
TOTAL ASSETS		**95,736**	**85,792**

Balance sheet
Parent company

Amount in kSEK	Note	2025-12-31	2024-12-31
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital		120,448	70,209
Statutory reserve		13,047	13,047
		133,495	**83,256**
Non-restricted capital			
Share premuim reserve		266,834	224,823
Accumulated deficit		-238,278	-190,703
Loss for the year		-68,996	-47,575
		-40,440	**-13,455**
Total equity		**93,055**	**69,801**
Short-term liabilities			
Accounts payable		406	721
Other liabilities		0	13,000
Accrued liabilities and deferred income		2,275	2,270
Total short-term liabilities		**2,681**	**15,991**
TOTAL EQUITY AND LIABILITIES		**95,736**	**85,792**

Statement of changes in parent company equity

Amount in kSEK	Share capital	Statutory reserve	Share premium reserve	Accumulated deficit incl. loss the year	Total equity
Opening balance 2025-01-01	**70,209**	**13,047**	**224,823**	**-238,278**	**69,801**
New share issue	50,239		50,149		100,388
Issuance costs			-8,138		-8,138
Loss of the year				-68,996	-68,996
Closing balance 2025-12-31	**120,448**	**13,047**	**266,834**	**-307,274**	**93,055**

Amount in kSEK	Share capital	Non registered share capital	Statutory reserve	Share premium reserve	Accumulated deficit incl. loss the year	Total equity
Opening balance 2024-01-01	**34,682**	**15,039**	**13,047**	**224,179**	**-190,703**	**96,244**
New share issue	35,527	-15,039		2,739		23,227
Issuance costs				-2,095		-2,095
Loss of the year					-47,575	-47,575
Closing balance 2024-12-31	**70,209**	**0**	**13,047**	**224,823**	**-238,278**	**69,801**

Cash flow statement, Parent company

Amount in kSEK	Note	2025-01-01 2025-12-31	2024-01-01 2024-12-31
The current operations			
Operating profit		-7,780	-6,177
Adjustment for non-cash items	10	-1,224	-3,060
Interest received		493	588
Cash flow from current operations before changes in working capital		**-8,511**	**-8,649**
Cash flow from changes in working capital			
Decrease(+)/increase(-) in operating receivables		-70	142
Decrease(-)/increase(+) in operating liabilities		215	666
Cash flow from investment activities		**-8,366**	**-7,841**
Investment activities			
Capital contribution paid		-48,451	-38,926
Cash flow from investment activities		**-48,451**	**-38,926**
Financing activities			
New share issue		81,437	52,329
Cash flow from financing activities		**81,437**	**52,329**
Cash flow		**24,620**	**5,562**
Cash at the beginning of the year		14,830	9,268
Cash and cash equivalents at the end of the year	8	**39,450**	**14,830**

Explanatory notes

NOTE 1 - ACCOUNTING AND MEASUREMENT PRINCIPLES

The Swedish Annual Accounts Act and the Swedish Accounting Standards Board's general advice BFNAR 2012:1 (K3) are applied when preparing financial reports.

ACCOUNTING CURRENCY

The Annual Report has been prepared in Swedish kronor (SEK), and amounts are presented in thousands of SEK (kSEK) unless otherwise stated.

CONSOLIDATED ACCOUNTS

The Consolidated Accounts include the parent company and the subsidiaries in which the parent company directly or indirectly holds more than 50% of the votes or otherwise has a controlling interest. The Consolidated Accounts have been prepared using the acquisition method. The purchase price for the business combination is measured at fair value at the acquisition date, which is calculated as the sum of the fair values at the acquisition date of assets paid, liabilities incurred or assumed, equity instruments issued, and expenses directly attributable to the business combination. Examples of expenses are transaction costs. The purchase price includes contingent consideration, provided that it is probable at the time of acquisition that the purchase price will be adjusted at a later date and that the amount can be reliably estimated. The value of the acquired entity is adjusted at the balance sheet date and when the final purchase price is determined, but not later than one year after the acquisition date.

In connection with business combinations where the total purchase price exceeds the fair value at the acquisition time of identifiable net assets acquired, the difference is recorded as goodwill in the consolidated balance sheet.

Intra-group profits are eliminated in full.

When translating foreign subsidiaries, the current rate method is used. This means that the balance sheets are translated at the foreign exchange rates prevailing at the balance sheet date, and that the income statements are translated at the average rates for the period. The translation differences arising are recorded directly in the Group's equity.

PARTICIPATIONS IN GROUP COMPANIES

Participations in group companies are reported in the parent company initially at the acquisition value, which includes any transaction costs that are directly attributable to the acquisition of the participations. Issuance proceeds and shareholder contributions are added to the acquisition value. Should the fair value be lower than the carrying amount, the shares are written down to their fair value if the decline in value is deemed to be permanent.

CASH FLOW STATEMENT

The cash flow statement has been prepared using the indirect method,adjusting for transactions that have not resulted in cash inflows or outflows. In addition to cash and bank balances, cash and cash equivalents are classified as balances on group accounts and short-term liquid investments that are readily convertible to a known amount and are subject to an insignificant risk of changes in value.

MEASUREMENT PRINCIPLES, ETC.

Assets, provisions, and liabilities are valued at cost unless otherwise stated below.

PROPRIETARY INTANGIBLE FIXED ASSETS

Development expenditures are reported according to the capitalization model as an intangible fixed asset, when the following criteria are met:

- it is technically and economically feasible to complete the asset,
- there is an intention and condition is to sell or use the asset,
- it is likely that the asset will generate income or result in cost savings,

• expenditure can be calculated satisfactorily.

• The acquisition value of an internally generated intangible asset consists of the directly attributable expenditure required to enable the asset to be used as intended by management.

TANGIBLE AND INTANGIBLE FIXED ASSETS

Tangible and intangible fixed assets are recorded at cost less scheduled depreciation based on an assessment of the useful life of the assets. The following depreciation periods apply to both the parent company and group companies:

Equipment	5 years

Capitalized development expenditure has not started depreciation because development has not been completed.

Intangible assets acquired in a business combination are identified and reported separately from goodwill when they meet the definition of an intangible asset and their fair values can be calculated reliably. The acquisition value of such intangible assets is their fair value at the time of acquisition.

EMPLOYEE BENEFITS

Benefits to employees, including salaries, bonuses, paid holidays, paid sick leave, and pensions, are recorded as they are earned. As for pensions and other post-employment benefits, these are classified as defined contribution or defined benefit pension plans. The Group only has defined contribution pension plans. There are no other long-term employee benefits.

FINANCIAL INSTRUMENTS

A financial asset or financial liability is recorded in the balance sheet when the Group becomes a party to the contractual terms of the instrument. A financial asset is derecognized when the contractual right to the cash flow from the asset expires, is settled, or when the Group loses control over it. A financial liability, or part of a financial liability, is derecognized when the contractual obligation is discharged or otherwise terminated.

Upon initial recognition, current assets and short-term liabilities are measured at cost. After initial recognition, the current asset is valued following the lowest value principle, i.e., the lower of cost and net realisable value at the balance sheet date. Short-term liabilities are valued at nominal value.

FOREIGN CURRENCY RECEIVABLES AND LIABILITIES

Receivables and liabilities in foreign currencies have been translated at the closing-day rate. The difference between the acquisition value and the value at the balance sheet date has been recorded in the profit and loss account. To the extent that foreign currency assets and liabilities have been hedged, they are translated at the forward rate.

IMPAIRMENTS

If there is an indication that an asset may be impaired, its recoverable amount is determined. If the asset's carrying amount exceeds its recoverable amount, the asset is written down to this value.The recoverable amount is defined as the higher of the market value and the value-in-use. Value-in-use is defined as the present value of the estimated future payments that the asset generates. Impairment is recorded in the profit and loss account.

Information on individual items

NOTE 2 - OTHER OPERATING INCOME

Amount in kSEK	Group 2025	Group 2024	Parent company 2025	Parent company 2024
NGM	219	112	219	112
Public contributions	4,083	10,877	0	0
Tax contribution R&D UK	9,992	8,105	0	0
Management fee Psyros Diagnostics Ltd. (Group)	0	0	3,060	3,060
Adjustment additional purchase price	12,556	0	0	0
Other	4	39	4	39
Total	**26,854**	**19,133**	**3,283**	**3,211**

NOTE 3 - AVERAGE NUMBER OF EMPLOYED AND SALARIES / BENEFITS

	Group 2025	Group 2024	Parent company 2025	Parent company 2024
Average number of employed				
Women	6	7	0	0
Men	16	14	0	0
Total	**22**	**21**	**0**	**0**
All employees are employed in the UK.				
Salaries, other benefits, and social costs including pension costs				
Board of Directors and CEO	1,120	1,180	1,120	1,180
Other employees	15,639	14,459	0	0
Other statutory and contractual social security costs	2,232	2,000	301	345
Total	**18,991**	**17,639**	**1,421**	**1,525**
Gender distribution among senior executives				
Proportion of women on the Board			29%	29%
Proportion of men on the Board			71%	71%

CEO Ulf Bladin has a consulting agreement with parent company and is not employed by the company. Total invoiced fees during the year amount to 3 349 (3 506) kSEK.

The company has outstanding warrants to employees of Psyros Diagnostics Ltd of 8,304,510 (equivalent to 83,045 shares) and 80,703 (equivalent to 80,703 shares) which may thus cause dilution.

NOTE 4 - CAPITALIZED DEVELOPMENT EXPENDITURE

	Group 2025-12-31	Group 2024-12-31	Parent company 2025-12-31	Parent company 2024-12-31
Opening acquisition value	241,155	138,000	113,300	113,300
Acquired intangible assets (reclassification)	0	85,922	0	0
Procurement	15,349	17,233	0	0
Closing accumulated acquisition values	**256,504**	**241,155**	**113,300**	**113,300**
Opening acumulated depreciation value	-113,300	-113,300	-113,300	-113,300
Write off additional purchase price	-15,928	0	0	0
Closing accumulated depreciation	**-129,228**	-113,300	**-113,300**	-113,300
Carrying amount	**127,276**	**127,855**	**0**	**0**

The acquired intangible asset of 85 MSEK consists of a development project in the form of Intangible assets consists of a new POC technology for digital immunoassay where individual molecules can be counted digitally from a drop of blood. This patent-pending technology, which also has the possibility of multiplexing, enables the measurement of biomarkers with extremely low detection levels within 10 minutes or less. The technology for this platform is to be able to measure extremely low concentrations of biomarkers such as high-sensitivity troponin.

This project has continued to be developed and the book value as of 2025-12-31 relates in its entirety to this project. The estimated completion is expected during 2027.

Impairment testing is carried out on an ongoing basis, and at the latest performance in Dec 2025 no impairment was indicated.

NOTE 5 - PATENTES

	Group 2025-12-31	Group 2024-12-31	Parent company 2025-12-31	Parent company 2024-12-31
Opening acquisition value	1,908	1,902	1,836	1,836
Translation difference for the year	0	6	0	0
Closing accumulated acquisition values	**1,908**	**1,908**	**1,836**	**1,836**
Opening depreciation	-48	-38	0	0
Depreciation for the year	-6	-7		
Write-off	-1,836	0	-1,836	0
Translation difference for the year	-3	-3		
Closing accumulated depreciation	**-1,893**	**-48**	**-1,836**	**0**
Carrying amount	**15**	**1,860**	**0**	**1,836**

NOTE 6 - EQUIPMENT, TOOLS, AND INSTALLATIONS

	Group 2025-12-31	Group 2024-12-31	Parent company 2025-12-31	Parent company 2024-12-31
Opening acquisition value	8,989	3,693	0	0
Procurement	4,260	5,025	0	0
Sales / scraped	-52			
Translation difference for the year	-929	271	0	0
Closing accumulated depreciation	**12,268**	**8,989**	**0**	**0**
Opening depreciation	-2,492	-999	0	0
Depreciation for the year	-1,864	-1,536	0	0
Sales / scraped	1			
Translation difference for the year	330	43	0	0
Closing accumulated depreciation	**-4,025**	**-2,492**	**0**	**0**
Carrying amount	**8,243**	**6,497**	**0**	**0**

NOTE 7 - PARTICIPATIONS IN GROUP CAMPANIES

In addition to the parent company, the following company is included in the Consolidated Accounts.

Comany	Corporate registration number	Residence	Capital share
Psyros Diagnostics Ltd.	11325521	Sandwhich, Kent	100%

	Parent company 2025-12-31	Parent company 2024-12-31
Opening acquisition value	166,824	124,838
Shareholders contributions	61,385	41,986
Closing acquisition value	**228,209**	**166,824**
Opening depreciation / amortization	-98,056	-56,070
Depreciation / amortization for the year	-61,385	-41,986
Adjustment additional purchase price	-13,000	
Closing accumulated depreciation	**-172,441**	**-98,056**
Carrying amount	**55,768**	**68,768**

The subsidiary's development activities are financed on an ongoing basis, including through contributions from the parent company. As these contributions have been used to cover losses in the subsidiary, they are written down on an ongoing basis in the parent company's accounts.

NOTE 8 - CASH AND CASH EQUIVALENTS

	Group 2025-12-31	Group 2024-12-31	Parent company 2025-12-31	Parent company 2024-12-31
Bank deposit	40,606	15,733	39,450	14,830
Total	40,606	15,733	39,450	14,830

NOTE 9 - COLLATERAL PROVIDED

	Group 2025-12-31	Group 2024-12-31	Parent company 2025-12-31	Parent company 2024-12-31
	None	None	None	None

NOTE 10 - NON-CASH FLOW ITEMS

	Group 2025-12-31	Group 2024-12-31	Parent company 2025-12-31	Parent company 2024-12-31
Depreciation / amortization	1,864	1,505	0	0
Depreciation in material assets	1,836	0	1,836	0
Management fee, shareholders contribution	0	0	-3,060	-3,060
Write down intagible assets	3,372	0	0	0
Other	7	0	0	0
Total	**7,079**	**1,505**	**-1,224**	**-3,060**

NOTE 11 - CONTINGENT LIABILITIES

	Group 2025-12-31	Group 2024-12-31	Parent company 2025-12-31	Parent company 2024-12-31
	None	None	None	None

NOTE 12 - ACQUIRED INTANGIBLE FIXED ASSETS

	Group 2025-12-31	Group 2024-12-31	Parent company 2025-12-31	Parent company 2024-12-31
Opening acquisition value	0	85,922	0	0
Adjusted acquisition analysis of intagible assets	0	0	0	0
Reclassification to note 4	0	-85,922	0	0
Closing accumulated acquisition value	**0**	**0**	**0**	**0**

The acquisition value of 85,922,459 arose through the acquisition of 100% of the shares in Psyros Diagnostics Ltd. The acquisition was made in March 2022. During the first quarter of 2023, the acquisition analysis was adjusted, whereby the intangible asset increased, and a deferred tax liability was recognized.

The purchase price, excluding transaction costs of 3.7 million SEK, consisted entirely of shares.

For more info see note 4.

NOTE 13 - TAXES

Loss carry-forward in Prolight Diagnostics AB amounts to 113 137 kSEK and in Psyros Diagnostics Ltd to 37 000 kSEK.

However, no deferred tax asset is recognized regarding the tax losses as there are no factors that convincingly indicate that sufficient tax surpluses will be generated.

NOTE 14 - ALLOCATION OF ACCUMULATED DEFICIT

The proposed appropriation of the Company`s loss

At the disposal of the Annual general Meeting is:	
Aaccumulated loss	-238,278
premium fond	266,834
loss of the year	-68,996
	-40,440
The Board proposes:	
dividends to shareholders	0
to be carried forward	-40,440
	-40,440

NOTE 15 - SIGNIFICANT EVENTS AFTER THE END OF THE FNANCIAL YEAR

- **Design freeze achieved for the Psyros instrument.**
- **Scale-up of cartridge manufacturing at FlexMedical Solutions.**
- **Strong interest in the Psyros POC system at the international WHX Labs congress.**
- **Positive results reported for traumatic brain injury (TBI) biomarkers in collaboration with BRAINBox Solutions, confirming broad platform potential.**
- **Selected as semi-finalist in the ADLM 2026 Disruptive Technology Award Competition.**
- **Prolight secures second patent in Japan for the Psyros technology.**

Signing of the annual report

LUND ON 5 MAY 2026

FREDRIK ALPSTEN
Chairman of the board

ULF BLADIN
CEO

MARIA HOLMLUND
Board member

TOBIAS VOLKER
Board member

AILEEN MCGETTRICK
Board member

STEVE ROSS
Board member

KIARASH FARR
Board member

Our audit report was submitted on 5 May 2026

Forvis Mazars AB

JESPER AHLKVIST
Chartered Accountant

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Growth Market marketplace, under the ticker PRLD.

For further information, please contact:
Prolight Diagnostics AB (publ)
E-mail: info@prolightdx.com
Telephone: +46 73 582 39 87
Website: www.prolightdx.com/en/

REVISIONSBERÄTTELSE

Till bolagsstämman i Prolight Diagnostics AB (publ)
Org. nr 556570-9499

Rapport om årsredovisningen och koncernredovisningen

Uttalanden

Vi har utfört en revision av årsredovisningen och koncernredovisningen för Prolight Diagnostics AB (publ) för år 2025. Bolagets årsredovisning ingår i den tryckta versionen av detta dokument på sidorna 16-42.

Enligt vår uppfattning har årsredovisningen och koncernredovisningen upprättats i enlighet med årsredovisningslagen och ger en i alla väsentliga avseenden rättvisande bild av moderbolagets och koncernens finansiella ställning per den 2025-12-31 och av dess finansiella resultat och kassaflöde för året enligt årsredovisningslagen. Förvaltningsberättelsen är förenlig med årsredovisningens och koncernredovisningens övriga delar.

Vi tillstyrker därför att bolagsstämman fastställer resultaträkningen och balansräkningen för moderbolaget och koncernen.

Grund för uttalanden

Vi har utfört revisionen enligt International Standards on Auditing (ISA) och god revisionssed i Sverige. Vårt ansvar enligt dessa standarder beskrivs närmare i avsnittet *Revisorns ansvar*. Vi är oberoende i förhållande till moderbolaget och koncernen enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

Väsentlig osäkerhetsfaktor avseende antagandet om fortsatt drift

Vi vill fästa uppmärksamheten på vad som framgår av förvaltningsberättelsen under rubriken "Finansieringsbehov och förutsättningar för fortsatt drift" där det framgår att bolaget, under 2026, kommer att vara i behov av ytterligare finansiering.

Utan ytterligare finansiering kommer bolagets kassa räcka till kvartal tre 2026. Skulle bolaget inte erhålla nödvändig finansiering, kan detta medföra att bolaget måste skjuta upp, dra ner på, eller avsluta delar av sin verksamhet.

Dessa förhållanden tyder på att det finns väsentliga osäkerhetsfaktorer som kan leda till betydande tvivel om bolagets förmåga att fortsätta sin verksamhet i nuvarande form.

Vi har inte modifierat våra uttalanden på grund av detta.

Annan information än årsredovisningen

Detta dokument innehåller även annan information än årsredovisningen och koncernredovisningen och återfinns på sidorna 1-15. Det är styrelsen och verkställande direktören som har ansvaret för den andra informationen.

Vårt uttalande avseende årsredovisningen omfattar inte denna information och vi gör inget uttalande med bestyrkande avseende denna andra information.

I samband med vår revision av årsredovisningen är det vårt ansvar att läsa den information som identifieras ovan och överväga om informationen i väsentlig utsträckning är oförenlig med årsredovisningen. Vid denna genomgång beaktar vi även den kunskap vi i övrigt inhämtat under revisionen samt bedömer om informationen i övrigt verkar innehålla väsentliga felaktigheter.

Om vi, baserat på det arbete som har utförts avseende denna information, drar slutsatsen att den andra informationen innehåller en väsentlig felaktighet, är vi skyldiga att rapportera detta. Vi har inget att rapportera i det avseendet.

Styrelsens och verkställande direktörens ansvar

Det är styrelsen och verkställande direktören som har ansvaret för att årsredovisningen och koncernredovisningen upprättas och att den ger en rättvisande bild enligt årsredovisningslagen. Styrelsen och verkställande direktören ansvarar även för den interna kontroll som de bedömer är nödvändig för att upprätta en årsredovisning och koncernredovisning som inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller på misstag.

Vid upprättandet av årsredovisningen och koncernredovisningen ansvarar styrelsen och verkställande direktören för bedömningen av bolagets och koncernens förmåga att fortsätta verksamheten. De upplyser, när så är tillämpligt, om förhållanden som kan påverka förmågan att fortsätta verksamheten och att använda antagandet om fortsatt drift. Antagandet om fortsatt drift tillämpas dock inte om styrelsen och verkställande direktören avser att likvidera bolaget, upphöra med verksamheten eller inte har något realistiskt alternativ till att göra något av detta.

Revisorns ansvar

Våra mål är att uppnå en rimlig grad av säkerhet om huruvida årsredovisningen och koncernredovisningen som helhet inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller på misstag, och att lämna en revisionsberättelse som innehåller våra uttalanden. Rimlig säkerhet är en hög grad av säkerhet, men är ingen garanti för att en revision som utförs enligt ISA och god revisionssed i Sverige alltid kommer att upptäcka en väsentlig felaktighet om en sådan finns. Felaktigheter kan uppstå på grund av oegentligheter eller misstag och anses vara väsentliga om de enskilt eller tillsammans rimligen kan förväntas påverka de ekonomiska beslut som användare fattar med grund i årsredovisningen och koncernredovisningen.

Som del av en revision enligt ISA använder vi professionellt omdöme och har en professionellt skeptisk inställning under hela revisionen. Dessutom:

- identifierar och bedömer vi riskerna för väsentliga felaktigheter i årsredovisningen och koncernredovisningen, vare sig dessa beror på oegentligheter eller på misstag, utformar och utför granskningsåtgärder bland annat utifrån dessa risker och inhämtar revisionsbevis som är tillräckliga och ändamålsenliga för att utgöra en grund för våra

uttalanden. Risken för att inte upptäcka en väsentlig felaktighet till följd av oegentligheter är högre än för en väsentlig felaktighet som beror på misstag, eftersom oegentligheter kan innefatta agerande i maskopi, förfalskning, avsiktliga utelämnanden, felaktig information eller åsidosättande av intern kontroll.

- skaffar vi oss en förståelse av den del av bolagets interna kontroll som har betydelse för vår revision för att utforma granskningsåtgärder som är lämpliga med hänsyn till omständigheterna, men inte för att uttala oss om effektiviteten i den interna kontrollen.
- utvärderar vi lämpligheten i de redovisningsprinciper som används och rimligheten i styrelsens och verkställande direktörens uppskattningar i redovisningen och tillhörande upplysningar.
- drar vi en slutsats om lämpligheten i att styrelsen och verkställande direktören använder antagandet om fortsatt drift vid upprättandet av årsredovisningen och koncernredovisningen. Vi drar också en slutsats, med grund i de inhämtade revisionsbevisen, om huruvida det finns någon väsentlig osäkerhetsfaktor som avser sådana händelser eller förhållanden som kan leda till betydande tvivel om bolagets och koncernens förmåga att fortsätta verksamheten. Om vi drar slutsatsen att det finns en väsentlig osäkerhetsfaktor, måste vi i revisionsberättelsen fästa uppmärksamheten på upplysningarna i årsredovisningen och koncernredovisningen om den väsentliga osäkerhetsfaktorn eller, om sådana upplysningar är otillräckliga, modifiera uttalandet om årsredovisningen och koncernredovisningen. Våra slutsatser baseras på de revisionsbevis som inhämtas fram till datumet för revisionsberättelsen. Dock kan framtida händelser eller förhållanden göra att ett bolag och en koncern inte längre kan fortsätta verksamheten.
- utvärderar vi den övergripande presentationen, strukturen och innehållet i årsredovisningen och koncernredovisningen, däribland upplysningarna, och om årsredovisningen och koncernredovisningen återger de underliggande transaktionerna och händelserna på ett sätt som ger en rättvisande bild.
- planerar och utför vi koncernrevisionen för att inhämta tillräckliga och ändamålsenliga revisionsbevis avseende den finansiella informationen för företag eller affärsenheter inom koncernen som grund för att göra ett uttalande avseende koncernredovisningen. Vi ansvarar för styrning, övervakning och genomgång av det revisionsarbete som utförts för koncernrevisionens syfte. Vi är ensamt ansvariga för våra uttalanden.

Vi måste informera styrelsen om bland annat revisionens planerade omfattning och inriktning samt tidpunkten för den. Vi måste också informera om betydelsefulla iakttagelser under revisionen, däribland de eventuella betydande brister i den interna kontrollen som vi identifierat.

Rapport om andra krav enligt lagar och andra författningar

Uttalanden

Utöver vår revision av årsredovisningen och koncernredovisningen har vi även utfört en revision av styrelsens och verkställande direktörens förvaltning för Prolight Diagnostics AB (publ) för år 2025 samt av förslaget till dispositioner beträffande bolagets vinst eller förlust.

Vi tillstyrker att bolagsstämman behandlar förlusten enligt förslaget i förvaltningsberättelsen och beviljar styrelsens ledamöter och verkställande direktören ansvarsfrihet för räkenskapsåret.

Grund för uttalanden

Vi har utfört revisionen enligt god revisionssed i Sverige. Vårt ansvar enligt denna beskrivs närmare i avsnittet *Revisorns ansvar*. Vi är oberoende i förhållande till moderbolaget och koncernen enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

Styrelsens och verkställande direktörens ansvar

Det är styrelsen som har ansvaret för förslaget till dispositioner beträffande bolagets vinst eller förlust. Vid förslag till utdelning innefattar detta bland annat en bedömning av om utdelningen är försvarlig med hänsyn till de krav som bolagets och koncernens verksamhetsart, omfattning och risker ställer på storleken av moderbolagets och koncernens egna kapital, konsolideringsbehov, likviditet och ställning i övrigt.

Styrelsen ansvarar för bolagets organisation och förvaltningen av bolagets angelägenheter. Detta innefattar bland annat att fortlöpande bedöma bolagets och koncernens ekonomiska situation och att tillse att bolagets organisation är utformad så att bokföringen, medelsförvaltningen och bolagets ekonomiska angelägenheter i övrigt kontrolleras på ett betryggande sätt. Den verkställande
direktören ska sköta den löpande förvaltningen enligt styrelsens riktlinjer och anvisningar och bland annat vidta de åtgärder som är nödvändiga för att bolagets bokföring ska fullgöras i överensstämmelse med lag och för att medelsförvaltningen ska skötas på ett betryggande sätt.

Revisorns ansvar

Vårt mål beträffande revisionen av förvaltningen, och därmed vårt uttalande om ansvarsfrihet, är att inhämta revisionsbevis för att med en rimlig grad av säkerhet kunna bedöma om någon styrelseledamot eller verkställande direktören i något väsentligt avseende:

- företagit någon åtgärd eller gjort sig skyldig till någon försummelse som kan föranleda ersättningsskyldighet mot bolaget, eller
- på något annat sätt handlat i strid med aktiebolagslagen, årsredovisningslagen eller bolagsordningen.

Vårt mål beträffande revisionen av förslaget till dispositioner av bolagets vinst eller förlust, och därmed vårt uttalande om detta, är att med rimlig grad av säkerhet bedöma om förslaget är förenligt med aktiebolagslagen.

Rimlig säkerhet är en hög grad av säkerhet, men ingen garanti för att en revision som utförs enligt god revisionssed i Sverige alltid kommer att upptäcka åtgärder eller försummelser som kan föranleda ersättningsskyldighet mot bolaget, eller att ett förslag till dispositioner av bolagets vinst eller förlust inte är förenligt med aktiebolagslagen.

Som en del av en revision enligt god revisionssed i Sverige använder vi professionellt omdöme och har en professionellt skeptisk inställning under hela revisionen. Granskningen av förvaltningen och förslaget till dispositioner av bolagets vinst eller förlust grundar sig främst på revisionen av räkenskaperna. Vilka tillkommande granskningsåtgärder som utförs baseras på vår professionella bedömning med utgångspunkt i risk och väsentlighet. Det innebär att vi fokuserar granskningen på sådana åtgärder, områden och förhållanden som är väsentliga för verksamheten och där avsteg och överträdelser skulle ha särskild betydelse för bolagets situation. Vi går igenom och prövar fattade beslut, beslutsunderlag, vidtagna åtgärder och andra förhållanden som är relevanta för vårt uttalande om ansvarsfrihet. Som underlag för vårt uttalande om styrelsens förslag till dispositioner beträffande bolagets vinst eller förlust har vi granskat om förslaget är förenligt med aktiebolagslagen.

Vår revisionsberättelse har lämnats i Lund den dag som framgår av vår elektroniska underskrift.

Forvis Mazars AB

Jesper Ahlkvist
Auktoriserad revisor